RxDoctor Payments Data

Sandhya Pattem, MD

Family Medicine · Jupiter, FLNPI 1639198856

Payments from drug & device makers

$400in general payments, 2019–2025

Across 20 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$138
  • Novartis$100
  • Novo Nordisk$64
  • Sunovion Pharmaceuticals Inc.$30
  • AstraZeneca$28
  • AbbVie$24
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$400 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$134,685
Medicare patients
275
Services billed
1,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$70,951
OzempicSemaglutide39$43,516
EliquisApixaban83$41,821
JardianceEmpagliflozin29$33,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$25,230
EntrestoSacubitril/Valsartan17$13,665
XareltoRivaroxaban12$10,662
LinzessLinaclotide13$7,146
Incruse ElliptaUmeclidinium Bromide23$2,861
Budesonide11$2,835
Breo ElliptaFluticasone/Vilanterol13$2,811
Methenamine Hippurate32$2,560
Gabapentin132$2,228
Atorvastatin Calcium143$2,026
Famotidine93$1,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$138$70,95170 claims
Novo NordiskOzempic$64$43,51639 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$16$30,90158 claims
NovartisEntresto$100$13,66517 claims
AbbVieLinzess$24$7,14613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →